Overview

ACCENDRA HEALTH INC/VA/

ACHNYSEHealth CareWholesale-Medical, Dental & Hospital Equipment & SuppliesCIK 0000075252

Latest 10-K: FY2025, filed Feb 21, 2026 · Open the 10-K (Inline XBRL) ↗

Revenue: $2.76B; 3.1%up from FY2024; TotalRevenue
Gross profit: $1.44B; 35.2%down from FY2024; GrossProfit
Operating income: $0.03B; n/m; OperatingIncome
Net income: -$1.10B; n/m; NetIncome
Diluted EPS: -$14.31; n/m; EPSDiluted

FY2025 versus the prior fiscal year.

At a glance

ACCENDRA HEALTH INC/VA/ reported revenue of $2.76B for fiscal 2025, up 3.1% from fiscal 2024.

Operating margin was 1.0% and net margin was -39.8%, against a median net margin of 12.8% across S&P 500 members for the same fiscal year.

Diluted EPS was -$14.31.

Revenue grew faster than the median S&P 500 member in 2 of the last 5 fiscal years.

Insiders reported no open-market purchases or sales on Form 4 in the past 12 months.

201 institutions reported holding ACCENDRA HEALTH INC/VA/ shares in 13F filings for the quarter ended June 30, 2026; the largest reported position was Christopher Shackelton's.

Data as of Oct 18, 2026 · Sources: SEC EDGAR 10-K, Form 4, 13F

Quick answers

What was ACCENDRA HEALTH INC/VA/'s revenue in fiscal 2025?: ACCENDRA HEALTH INC/VA/ reported revenue of $2.76B for fiscal 2025, up 3.1% from fiscal 2024.
What is ACCENDRA HEALTH INC/VA/'s net margin?: Operating margin was 1.0% and net margin was -39.8%, against a median net margin of 12.8% across S&P 500 members for the same fiscal year.
What is ACCENDRA HEALTH INC/VA/'s diluted EPS?: Diluted EPS was -$14.31.
Are ACCENDRA HEALTH INC/VA/ insiders buying or selling shares?: Insiders reported no open-market purchases or sales on Form 4 in the past 12 months.
Which institutions hold ACCENDRA HEALTH INC/VA/ stock?: 201 institutions reported holding ACCENDRA HEALTH INC/VA/ shares in 13F filings for the quarter ended June 30, 2026; the largest reported position was Christopher Shackelton's.

Data as of Oct 18, 2026 · Sources: SEC EDGAR 10-K

Data as filed with the SEC, provided for information only — not investment advice.

Every figure Valuein returns traces to its SEC filing. How we build this data →

Earnings power

Five fiscal years of revenue and earnings, with the change from the prior year and the five-year compound growth — compared with the typical S&P 500 company.

Annual earnings, newest fiscal year first. Chip: change versus the prior year. Muted line: S&P 500 median change.
Line item	FY2025	FY2024	FY2023	FY2022	FY2021	5Y CAGR
Revenue	$2.76B3.1%up S&P 500 6.4%	$2.68B5.0%up S&P 500 4.6%	$2.55B74.4%down S&P 500 4.9%	$9.96B1.7%up S&P 500 9.7%	$9.79B15.4%up S&P 500 14.8%	-27.1%
Gross profit	$1.44B35.2%down	$2.22B4.4%up	$2.13B16.4%up	$1.83B20.7%up	$1.51B18.1%up	-1.3%
Operating income	$0.03Bn/m	-$0.22B263.4%down	$0.13B6.8%down	$0.14B61.2%down	$0.37B80.5%up	-47.8%
Net income	-$1.10Bn/m S&P 500 4.7%	-$0.36Bn/m S&P 500 5.7%	-$0.04B284.5%down S&P 500 1.7%	$0.02B89.9%down S&P 500 1.8%	$0.22B641.8%up	n/m
EPS (diluted)	-$14.31n/m S&P 500 6.1%	-$4.73n/m S&P 500 7.9%	-$0.53282.8%down S&P 500 1.3%	$0.2990.1%down S&P 500 1.2%	$2.94525.5%up	n/m

n/m: not meaningful — the base (the prior year, or the first year for the 5Y CAGR) was zero or negative. “—” means the figure is not available.

S&P 500 median = median of the companies in the index on Dec 31 of each fiscal year, from their own 10-K filings; a change counts only companies whose prior year was positive. Published only where at least 400 members report the line item. Updated 2026-10-18. This compares reported earnings, not share-price returns. Methodology

Financial statements

Annual figures from the 10-K, most recent fiscal year first.

Income Statement

5 annual periods

Income Statement, annual, most recent fiscal year first
Metric	FY25Dec '25	FY24Dec '24	FY23Dec '23	FY22Dec '22	FY21Dec '21	5Y CAGR
Revenue	$2.76B3.1%up	$2.68B5.0%up	$2.55B74.4%down	$9.96B1.7%up	$9.79B15.4%up	-27.1%
Gross Profit	$1.44B35.2%down	$2.22B4.4%up	$2.13B16.4%up	$1.83B20.7%up	$1.51B18.1%up	-1.3%
Operating Income	$0.03Bn/m	negative: -$0.22B263.4%down	$0.13B6.8%down	$0.14B61.2%down	$0.37B80.5%up	-47.8%
Net Income	negative: -$1.10Bn/m	negative: -$0.36Bn/m	negative: -$0.04B284.5%down	$0.02B89.9%down	$0.22B641.8%up	n/m
EPS (Diluted)	negative: -$14.31n/m	negative: -$4.73n/m	negative: -$0.53282.8%down	$0.2990.1%down	$2.94525.5%up	n/m

Chip: change versus the prior fiscal year (n/m when the prior year was zero or negative). 5Y CAGR: compound annual growth from the oldest to the newest year shown.

Balance Sheet

5 annual periods

Balance Sheet, annual, most recent fiscal year first
Metric	FY25Dec '25	FY24Dec '24	FY23Dec '23	FY22Dec '22	FY21Dec '21	5Y CAGR
Total Assets	$2.45B47.3%down	$4.66B8.6%down	$5.09B5.4%down	$5.39B52.3%up	$3.54B6.0%up	-8.8%
Total Liabilities	$2.91B28.4%down	$4.07B2.4%down	$4.17B6.1%down	$4.44B70.9%up	$2.60B1.0%down	2.9%
Stockholders' Equity	negative: -$0.46B178.6%down	$0.59B38.0%down	$0.95B2.2%down	$0.97B3.0%up	$0.94B31.8%up	n/m
Cash & Equivalents	$0.28B922.7%up	$0.03B88.7%down	$0.24B249.9%up	$0.07B24.7%up	$0.06B32.9%down	50.0%
Total Debt	$1.80B0.1%up	$1.80B4.9%down	$1.89B23.9%down	$2.48B162.0%up	$0.95B3.9%down	17.4%

Chip: change versus the prior fiscal year (n/m when the prior year was zero or negative). 5Y CAGR: compound annual growth from the oldest to the newest year shown.

Cash Flow Statement

5 annual periods

Cash Flow Statement, annual, most recent fiscal year first
Metric	FY25Dec '25	FY24Dec '24	FY23Dec '23	FY22Dec '22	FY21Dec '21	5Y CAGR
Operating Cash Flow	—	$0.16B78.2%down	$0.74B127.9%up	$0.33B161.7%up	$0.12B63.4%down	—
Capital Expenditures	$0.19B12.1%up	$0.17B1.2%down	$0.17B3.5%up	$0.17B235.2%up	$0.05B16.1%down	40.0%
Free Cash Flow	—	negative: -$0.01B101.5%down	$0.57B258.7%up	$0.16B112.7%up	$0.07B73.4%down	—

Chip: change versus the prior fiscal year (n/m when the prior year was zero or negative). 5Y CAGR: compound annual growth from the oldest to the newest year shown.

Ratios & valuation

FY2025

Ratios and valuation for fiscal year 2025: each Wall Street metric beside its value-investor counterpart
Wall Street view	FY2025	Value-investor view	FY2025
Wall Street viewEV / EBITDA	7.2×FY2024: 48.4×	Value-investor viewEV / EBIT	63.1×FY2024: n/m
Wall Street viewPrice / sales	0.1×FY2024: 0.1×	Value-investor viewFCF margin	— Not reportedFY2024: -0.3%
Wall Street viewReturn on equity	— Not reportedFY2024: -47.4%	Value-investor viewReturn on invested capital	-1.5%FY2024: -6.1%
Wall Street viewReturn on assets	-31.0%FY2024: -7.4%	Value-investor viewCash return on assets	— Not reportedFY2024: -0.2%
Wall Street viewDiluted EPS	-$14.31FY2024: -$4.73	Value-investor viewFCF per diluted share	— Not reportedFY2024: -$0.11
Wall Street viewCurrent ratio	0.58×FY2024: 1.09×	Value-investor viewQuick ratio	0.50×FY2024: 1.05×

Multiples use the fiscal-year-end closing price. Free cash flow = operating cash flow − capital expenditures (we compute it; filings rarely report it). n/m = not meaningful (denominator ≤ 0); “—” = not reported. Hover a metric for its formula.

Cash & capital allocation

Where the cash went in FY2025, from the 10-K cash flow statement.

Operating cash flow: —
Capex: $190.96M
Free cash flow: —
R&D: —
Buybacks: $10.18M
Dividends: —
Debt repaid: —
Debt issued: —
Net debt change: —

Uses of operating cash flow, FY2025

The uses split was not reported for this year.

Each use is shown against operating cash flow on its own; the uses overlap.

Free cash flow by year

FY21$74.49M
FY22$158.42M
FY23$568.34M
FY24-$8.79M
FY25—

Buybacks by year

FY21—
FY22—
FY23—
FY24—
FY25$10.18M

Smart money

Who is trading and holding ACCENDRA HEALTH INC/VA/, from Form 4, 13F and 13D/13G filings.

Insiders

Insider activity · past 12 months

No open-market insider purchases or sales were reported on Form 4 in the past 12 months.

Open-market purchases (code P) and sales (code S) only. Grants, option exercises and tax withholding are excluded. Sales may be made under pre-arranged Rule 10b5-1 plans.

Ownership

Largest institutional holders · 13F, quarter ended Jun 30, 2026

201 institutions reported positions.

Top institutional holders from 13F filings
Holder	Shares	Value	Filing
Christopher Shackelton	13,100,807	$44.8M	View filing on SEC EDGAR
BANK OF AMERICA CORP /DE/	3,275,937	$11.2M	View filing on SEC EDGAR
Vanguard Capital Management	3,087,931	$10.6M	View filing on SEC EDGAR
BlackRock, Inc.	2,968,294	$10.2M	View filing on SEC EDGAR
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	2,888,058	$9.9M	View filing on SEC EDGAR

13F filings are due 45 days after quarter end, so this shows the latest fully reported quarter. Amended filings are counted once.

Blockholders, 5% and over · SC 13D / 13G

Latest 13D and 13G filing per holder of 5% or more
Holder	Stake	Form	Filed	Filing
Coliseum Capital Management, LLC	16.9%	SC 13D	Nov 14, 2025	View filing on SEC EDGAR
Coliseum Capital Partners, L.P.	13.8%	SC 13D	Nov 14, 2025	View filing on SEC EDGAR
BANK OF AMERICA CORP /DE/	10.8%	SC 13G	Oct 7, 2026	View filing on SEC EDGAR
BlackRock, Inc.	7.1%	SC 13G/A	Oct 2, 2025	View filing on SEC EDGAR
Deerfield Management	6.84%	SC 13G/A	Feb 12, 2024	View filing on SEC EDGAR
Kevin M. Webb	5.61%	SC 13G	Mar 30, 2026	View filing on SEC EDGAR

Switched from 13G to 13D in the last 365 days: Coliseum Capital Management, LLC, Coliseum Capital Partners, L.P..

Latest filing per filer within three years; a later filing reporting 0% removes the filer.

Full history, every insider and 13F filer, 13D/G activist stakes, and webhooks are on Institutional.

See Institutional

Smart money

Showing the most recent 5 annual periods. Get longer history on the Pro plan, or the full history (1993–present) plus the smart-money dataset and webhooks on Institutional.

Restatement Radar

6 numbers ACCENDRA HEALTH INC/VA/ later changed — same XBRL tag, both filings linked.

Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest·Q1 2025
Major restatement
-$5.4M▲ 84.6%
was-$35.1M
Revised up in a 10-Q.
No amendment filed
As reported · May 9, 2025 10-Q · May 11, 2026us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Revenue from Contract with Customer, Excluding Assessed Tax·FY 2023
Major restatement
$2.6B▼ 75.3%
was$10.3B
Revised down in a 10-K. Any P/S built on the original was 304.8% too low.
No amendment filed
As reported · Feb 21, 2024 10-K · Feb 21, 2026us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue from Contract with Customer, Excluding Assessed Tax·Q2 2024
Major restatement
$660.4M▼ 75.3%
was$2.7B
Revised down in a 10-Q. Any P/S built on the original was 304.5% too low.
No amendment filed
As reported · Aug 3, 2024 10-Q · Aug 12, 2025us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue from Contract with Customer, Excluding Assessed Tax·FY 2024
Major restatement
$2.7B▼ 75.0%
was$10.7B
Revised down in a 10-K. Any P/S built on the original was 299.3% too low.
No amendment filed
As reported · Mar 1, 2025 10-K · Feb 21, 2026us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue from Contract with Customer, Excluding Assessed Tax·Q3 2024
Major restatement
$686.8M▼ 74.8%
was$2.7B
Revised down in a 10-Q. Any P/S built on the original was 296.2% too low.
No amendment filed
As reported · Nov 5, 2024 10-Q · Oct 31, 2025us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue from Contract with Customer, Excluding Assessed Tax·Q1 2025
Major restatement
$673.9M▼ 74.4%
was$2.6B
Revised down in a 10-Q. Any P/S built on the original was 290.6% too low.
No amendment filed
As reported · May 9, 2025 10-Q · May 11, 2026us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax

ACH is not the only one.

See every restatement we've found across the market — or get an alert the next time ACH revises a number.

Restatement Radar Alert me

Restatements are detected by comparing every vintage of a fact across all of ACCENDRA HEALTH INC/VA/'s filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows ACH's most significant revisions, and a figure absent from it has not been certified as unrevised.

Peers, filings & research

Sector Peers

UNITEDHEALTH GROUP INC

MRK· Health Care

Merck & Co., Inc.

TMO· Health Care

THERMO FISHER SCIENTIFIC INC.

ABT· Health Care

ABBOTT LABORATORIES

ISRG· Health Care

INTUITIVE SURGICAL INC

AMGN· Health Care

AMGEN INC

Recent SEC filings (by form type, newest first)

Form	Accession ID	Report Date	Filing Date	Accepted At	Source
8-K	0001104659-26-115043	Oct 6, 2026	Oct 9, 2026	Oct 10, 2026 00:10 UTC	EDGAR
8-K	0001104659-26-108405	Sep 16, 2026	Sep 17, 2026	Sep 17, 2026 14:35 UTC	EDGAR
8-K	0001104659-26-097517	Aug 17, 2026	Aug 17, 2026	Aug 17, 2026 14:42 UTC	EDGAR
10-Q	0001104659-26-093177	Jun 30, 2026	Aug 10, 2026	Aug 10, 2026 19:15 UTC	EDGAR
10-Q	0001104659-26-058465	Mar 31, 2026	May 11, 2026	May 11, 2026 19:59 UTC	EDGAR
10-K	0001104659-26-018169	Dec 31, 2025	Feb 20, 2026	Feb 21, 2026 02:19 UTC	EDGAR
10-Q	0001104659-25-104506	Sep 30, 2025	Oct 31, 2025	Oct 31, 2025 01:35 UTC	EDGAR
10-K	0001558370-25-001940	Dec 31, 2024	Feb 28, 2025	Mar 1, 2025 02:05 UTC	EDGAR
10-Q/Aamend	0001193125-08-195362	Jun 30, 2008	Sep 12, 2008	Sep 13, 2008 00:41 UTC	EDGAR
10-Q/Aamend	0001193125-08-195360	Mar 31, 2008	Sep 12, 2008	Sep 13, 2008 00:40 UTC	EDGAR
10-Q/Aamend	0001193125-08-193107	Jun 30, 2008	Sep 9, 2008	Sep 10, 2008 01:17 UTC	EDGAR
10-K/Aamend	0001193125-07-040014	Dec 31, 2006	Feb 27, 2007	Feb 27, 2007 04:50 UTC	EDGAR
10-K/Aamend	0000075252-94-000015	Dec 31, 1993	Jun 21, 1994	Jun 21, 1994 12:00 UTC	EDGAR

Direct links to SEC EDGAR. ACH has additional filings available on the SEC site.

Research Reports

No published research on ACH yet.

Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows on data pinned to its SEC filing. Be the first: run equity_research_brief on ACH and publish the result to your public profile.

Browse the research catalog Generate one with your agent

The data behind this page

27 tables, history 1993–present. Every figure above is a row you can query.

Fundamentals

Standardized financial facts, ratios and filings.

fact: 120.5Mrows
ratio: 5.3Mrows
filing: 2.35Mrows
entity: 19,888rows

292 standard concepts.

Built from these SEC forms

10-K+/A
10-Q+/A
20-F+/A
40-F+/A
6-K+/A
8-K+/A
10-K405+/A
10-KT+/A
10-KSB+/A
10-QT+/A
10-QSB+/A
S-1+/A
S-3+/A
S-4+/A
S-11+/A
F-1+/A
F-3+/A
F-4+/A
POS AM

Smart money

Insider and institutional filings.

institutional_holding: 59.5Mrows
insider_transaction: 11.4Mrows
insider_filing: 5.2Mrows
insider_ownership: 1.33Mrows

78M+ smart-money rows in all.

Built from these SEC forms

Form 3+/A
Form 4+/A
Form 5+/A
Form 144+/A
13F-HR+/A
SC 13D+/A
SC 13G+/A
Schedule 13D+/A
Schedule 13G+/A
Form ADV

Get the same data

Get your free API key

bash

curl -H "Authorization: Bearer $VALUEIN_API_KEY" \  https://data.valuein.biz/v1/pro/fact/0000075252.parquet \  -o ach.parquet

Terminalbash

$ pip install valuein-sdk

Python

from valuein_sdk import ValueinClient with ValueinClient() as client:    sql = """        SELECT fiscal_year, numeric_value FROM fact        WHERE entity_id = '0000075252'          AND standard_concept = 'TotalRevenue'          AND fiscal_period = 'FY'    """    print(client.run_query(sql))

bash

https://mcp.valuein.biz/mcp Ask your agent:get_company_fundamentals ACH   # CIK 0000075252

One token unlocks every channel. SDK docs · MCP docs

Cite this page

Data as of Oct 18, 2026. Canonical address: https://valuein.biz/data/ACH

APA-style text

Valuein. (2026, October 18). ACCENDRA HEALTH INC/VA/ (ACH) financial statements, earnings power and smart-money summary [Data set]. Source: SEC EDGAR filings. https://valuein.biz/data/ACH

BibTeX

@misc{valuein_ach_2026,
  author = {{Valuein}},
  title = {ACCENDRA HEALTH INC/VA/ (ACH) financial statements, earnings power and smart-money summary},
  year = {2026},
  howpublished = {\url{https://valuein.biz/data/ACH}},
  note = {Data as of 2026-10-18; source: SEC EDGAR filings}
}

Open 10-K in SEC Inline XBRL viewer

10-K filed Feb 20, 2026 · accession 0001104659-26-018169

Agents: every figure Valuein's tools return carries a fact_id that traces to its SEC filing.

point-in-time · survivorship-free · every number traceable to its SEC filing

View ACH filings on SEC EDGAR

At a glance

02Earnings power

03Financial statements

Income Statement

Balance Sheet

Cash Flow Statement

Ratios & valuation

04Cash & capital allocation

Uses of operating cash flow, FY2025

Free cash flow by year

Buybacks by year

05Smart money

Insiders

Insider activity · past 12 months

Ownership

Largest institutional holders · 13F, quarter ended Jun 30, 2026

Blockholders, 5% and over · SC 13D / 13G

Smart money

07Peers, filings & research

Sector Peers

Recent SEC filings (by form type, newest first)

Research Reports

08The data behind this page

Fundamentals

Built from these SEC forms

Smart money

Built from these SEC forms

Get the same data

09Cite this page

04Cash & capital allocation

Uses of operating cash flow, FY2025

Free cash flow by year

Buybacks by year

05Smart money

Insiders

Insider activity · past 12 months

Ownership

Largest institutional holders · 13F, quarter ended Jun 30, 2026

Blockholders, 5% and over · SC 13D / 13G

Sector Peers

Recent SEC filings (by form type, newest first)

08The data behind this page

Fundamentals

Built from these SEC forms

Smart money

Built from these SEC forms

Get the same data

Earnings power

Financial statements

Cash & capital allocation

Smart money

Peers, filings & research

The data behind this page

Cite this page

Cash & capital allocation

Smart money

The data behind this page